PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 16, 2015--
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it
received a subpoena from the U.S. Department of Justice, U.S. Attorney’s
Office for the District of New Jersey, requiring the production of a
broad range of documents pertaining to marketing and promotional
practices related to the product EXPAREL® (bupivacaine liposome
injectable suspension). Pacira intends to cooperate with the
government’s investigation.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s flagship product, EXPAREL®
(bupivacaine liposome injectable suspension), a non-opioid local
analgesic for postsurgical pain control, was commercially launched in
the United States in April 2012. EXPAREL and two other products have
successfully utilized DepoFoam®, a unique and proprietary
product delivery technology that encapsulates drugs without altering
their molecular structure, and releases them over a desired period of
time. Additional information about Pacira is available at www.pacira.com.
Forward Looking Statements
Any statements in this press release about our future expectations,
plans, outlook and prospects, including statements about our expected
revenues, and other statements containing the words “believes,”
“anticipates,” “plans,” “estimates,” “expects,” and similar expressions,
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including risks relating to: the
success of our sales and manufacturing efforts in support of the
commercialization of EXPAREL; the rate and degree of market acceptance
of EXPAREL; the size and growth of the potential markets for EXPAREL and
our ability to serve those markets; our plans to expand the use of
EXPAREL to additional indications, including nerve block, oral surgery
and chronic pain, as well as pediatrics; the related timing and success
of a United States Food and Drug Administration supplemental New Drug
Application; our receipt of FDA approval of our nerve block indication;
the adverse effects and impacts of FDA warning letters; the outcome of
the Department of Justice inquiry; our plans to evaluate, develop and
pursue additional DepoFoam-based product candidates; clinical studies in
support of an existing or potential DepoFoam-based product; our plans to
continue to manufacture and provide support services for our commercial
partners who have licensed DepoCyt(e); our commercialization and
marketing capabilities; our and Patheon UK Limited’s ability to
successfully and timely construct dedicated EXPAREL manufacturing
suites; and other factors discussed in the “Risk Factors” of our most
recent Annual Report on Form 10-K for the fiscal year ended December 31,
2014, and in other filings that we periodically make with the SEC. In
addition, the forward-looking statements included in this press release
represent our views as of the date of this press release. Important
factors could cause our actual results to differ materially from those
indicated or implied by forward-looking statements, and as such we
anticipate that subsequent events and developments will cause our views
to change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so. These forward-looking statements should not be
relied upon as representing our views as of any date subsequent to the
date of this press release.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574
or
Media
Contact:
Pure Communications, Inc.
Dan Budwick,
973-271-6085